

# John H Strickler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1234783/publications.pdf>

Version: 2024-02-01

110  
papers

3,497  
citations

304368

22  
h-index

155451

55  
g-index

110  
all docs

110  
docs citations

110  
times ranked

5699  
citing authors

#	ARTICLE	IF	CITATIONS
1	KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
2	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2654-2668.	0.8	292
3	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 164-173.	7.7	243
4	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. <i>Clinical Cancer Research</i> , 2021, 27, 1236-1241.	3.2	222
5	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
6	Sotorasib for previously treated colorectal cancers with KRAS <sup>G12C</sup> mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2022, 23, 115-124.	5.1	147
7	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3298-3306.	0.8	88
8	Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 3156-3167.	3.2	79
9	Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Oncologist</i> , 2012, 17, 513-524.	1.9	67
10	A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2019, 8, 5148-5157.	1.3	60
11	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 851-859.	1.1	53
12	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	1.0	53
13	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017, 60, 109-119.	3.4	45
14	Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 251-258.	1.1	43
15	Development of a Novel c-MET-Based CTC Detection Platform. <i>Molecular Cancer Research</i> , 2016, 14, 539-547.	1.5	37
16	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. <i>Cell Reports</i> , 2021, 35, 109071.	2.9	35
17	First data for sotorasib in patients with pancreatic cancer with KRAS <sup>G12C</sup> p.G12C mutation: A phase I/II study evaluating efficacy and safety. <i>Journal of Clinical Oncology</i> , 2022, 40, 360490-360490.	0.8	34
18	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	3.2	30

#	ARTICLE	IF	CITATIONS
19	A phase I dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.	2.9	29
20	A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 882-892.	3.2	29
21	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9047-9047.	0.8	28
22	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, ehv611.	1.0	25
23	MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS153-TPS153.	0.8	24
24	Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1614-1622.	0.9	23
25	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS <sup>G12C</sup> , in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4018-4018.	0.8	22
26	<i>BRAF</i>-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	0.8	21
27	Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2240-2249.	1.9	20
28	Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2507-2507.	0.8	20
29	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 330-339.	1.2	18
30	Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 5086-5095.	0.7	18
31	Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 167-167.	0.8	18
32	Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4074-4074.	0.8	18
33	Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1210-1217.	1.9	17
34	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252.	0.8	16
35	Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 279-279.	0.8	16
36	Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 305.	1.3	15

#	ARTICLE	IF	CITATIONS
37	<scp>First-In-Human</scp>, <scp>First-In-Class</scp>, Phase I Trial of the Fucosylation Inhibitor <scp>SGN-2FF</scp> in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, 925-e1918.	1.9	15
38	Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 166-169.	0.6	14
39	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3011-3011.	0.8	14
40	A phase 1b study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 909-917.	1.1	13
41	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917.	1.9	13
42	Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 500-509.	1.1	13
43	A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3624-TPS3624.	0.8	13
44	DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.. <i>Journal of Clinical Oncology</i> , 2020, 38, 357-357.	0.8	13
45	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. <i>Annual Review of Medicine</i> , 2021, 72, 399-413.	5.0	12
46	Development and validation of a patient-reported tool to evaluate legal and financial needs in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 174-174.	0.8	11
47	Maintenance Therapy for First-Line Metastatic Colorectal Cancer: Activity and Sustainability. <i>Oncologist</i> , 2012, 17, 9-10.	1.9	10
48	Clinical applications of liquid biopsies in gastrointestinal oncology. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 675-686.	0.6	10
49	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. <i>Current Oncology Reports</i> , 2014, 16, 363.	1.8	9
50	A phase 1b study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.	1.1	9
51	Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 114-120.	0.7	9
52	Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 112-121.	1.1	8
53	Final results of phase 1b of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-278.	0.8	8
54	A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type <i>RAS</i> metastatic colorectal cancer in the US. <i>Journal of Medical Economics</i> , 2018, 21, 1075-1083.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 161-173.	1.8	7
56	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2020, 38, e16686-e16686.	0.8	7
57	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€”Trial in progress.. Journal of Clinical Oncology, 2022, 40, TPS371-TPS371.	0.8	7
58	EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?. Cancer Discovery, 2018, 8, 679-681.	7.7	6
59	Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacicab in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2021, 20, 1988-1995.	1.9	6
60	PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, TPS143-TPS143.	0.8	5
61	Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2510-2510.	0.8	5
62	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational New Drugs, 2014, 32, 700-709.	1.2	4
63	Targeting <i>MET</i> Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma. Cancer Investigation, 2021, 39, 235-239.	0.6	4
64	Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. JCO Precision Oncology, 2021, 5, 1493-1506.	1.5	4
65	Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3548-3548.	0.8	4
66	A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS3096-TPS3096.	0.8	4
67	Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 2509-2509.	0.8	4
68	Paracrine wnt-Î²-catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.. Journal of Clinical Oncology, 2017, 35, 3053-3053.	0.8	4
69	Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.. Journal of Clinical Oncology, 2018, 36, 3507-3507.	0.8	4
70	Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.. Journal of Clinical Oncology, 2020, 38, 80-80.	0.8	4
71	Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS376-TPS376.	0.8	4
72	Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. Targeted Oncology, 2021, 16, 109-118.	1.7	3

#	ARTICLE	IF	CITATIONS
73	Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2507-2507.	0.8	3
74	Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.. Journal of Clinical Oncology, 2017, 35, 161-161.	0.8	3
75	A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.. Journal of Clinical Oncology, 2018, 36, 3555-3555.	0.8	3
76	Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology, 2021, 35, 654-660.	0.4	3
77	Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease. Circulation, 2019, 140, 1460-1462.	1.6	2
78	KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, 228-228.	0.8	2
79	Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).. Journal of Clinical Oncology, 2016, 34, e15013-e15013.	0.8	2
80	ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.. Journal of Clinical Oncology, 2018, 36, TPS3619-TPS3619.	0.8	2
81	Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 641-641.	0.8	2
82	Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.. Journal of Clinical Oncology, 2019, 37, 3552-3552.	0.8	2
83	A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with <i>MET</i> amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.. Journal of Clinical Oncology, 2020, 38, TPS270-TPS270.	0.8	2
84	Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. Cancer Chemotherapy and Pharmacology, 2022, 89, 413-422.	1.1	2
85	Gastroesophageal Heterotopia and HER2/neu Overexpression in an Adenocarcinoma Arising From a Small Bowel Duplication. Archives of Pathology and Laboratory Medicine, 2014, 138, 428-431.	1.2	1
86	Characterization of the Epidermal Growth Factor Receptor T790M Mutation in Colorectal Cancer. JCO Precision Oncology, 2018, 2, 1-7.	1.5	1
87	Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling.. Journal of Clinical Oncology, 2021, 39, 39-39.	0.8	1
88	Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.. Journal of Clinical Oncology, 2021, 39, 3572-3572.	0.8	1
89	The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. Oncology, 2021, 35, 553-559.	0.4	1
90	X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 687-687.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).. Journal of Clinical Oncology, 2017, 35, 584-584.	0.8	1
92	ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.. Journal of Clinical Oncology, 2019, 37, TPS720-TPS720.	0.8	1
93	Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 604-604.	0.8	1
94	Quantifying the evolution of tumor architecture using serial circulating tumor DNA.. Journal of Clinical Oncology, 2019, 37, 600-600.	0.8	1
95	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1511.	3.4	0
96	ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. Annals of Surgical Oncology, 2020, 27, 804-805.	0.7	0
97	Clonal hematopoiesis association with cardiac function and mortality in patients with solid tumors.. Journal of Clinical Oncology, 2021, 39, 10586-10586.	0.8	0
98	MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study.. Journal of Clinical Oncology, 2012, 30, 3039-3039.	0.8	0
99	Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 11036-11036.	0.8	0
100	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2574-2574.	0.8	0
101	Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.. Journal of Clinical Oncology, 2015, 33, 11024-11024.	0.8	0
102	Identification of novel <i>EGFR</i> ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests.. Journal of Clinical Oncology, 2016, 34, e23167-e23167.	0.8	0
103	Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 3590-3590.	0.8	0
104	Genetic counseling referrals after next generation sequencing testing.. Journal of Clinical Oncology, 2020, 38, 1515-1515.	0.8	0
105	The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.. Journal of Clinical Oncology, 2020, 38, 1516-1516.	0.8	0
106	409â€¦A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).., 2020, , .		0
107	REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.. Journal of Clinical Oncology, 2022, 40, TPS213-TPS213.	0.8	0
108	Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.. Journal of Clinical Oncology, 2022, 40, 120-120.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.. Journal of Clinical Oncology, 2022, 40, 4086-4086.	0.8	0
110	Frequency of practice-changing findings identified by comprehensive genomic profiling in non-myeloid hematologic malignancies.. Journal of Clinical Oncology, 2022, 40, 3060-3060.	0.8	0